Department of Oncology, Yancheng Third People's Hospital & The Sixth Affiliated Hospital of Nantong University, Yancheng, Jiangsu Province 224008, China.
Comput Math Methods Med. 2022 Jun 28;2022:8036763. doi: 10.1155/2022/8036763. eCollection 2022.
Although adjuvant therapy has been shown to be beneficial in gastric cancer, the use of adjuvant chemoradiotherapy remains controversial. This paper investigated the effects of postoperative adjuvant chemoradiotherapy on the survival of patients with stage III gastric cancer.
In total, the data of 72 stage III gastric cancer patients treated at our hospital from January 2014 to December 2019 were retrieved and assessed. They were categorized into a chemotherapy group (CT group) and a radiochemotherapy group (RCT group) according to their given treatment regimens. A 3-year follow-up was conducted to record their incidence of disease-free survival (DFS), overall survival (OS), and adverse events.
For the CT and RCT groups, DFS was 86.4% and 92.6% in the first year, decreasing to 55.1% and 73.7% in the second year, and 41.3% and 69.1% in the third year. There was no significant difference in DFS between the two groups during the three-year follow-up. Additionally, for the CT and RCT groups, their respective 1-year, 2-year, and 3-year OS were 95.6% and 96.3%, 75.1% and 87.9%, and 50.3% and 74.2%, indicating that the OS of patients in the RCT group was significantly higher than that in the CT group during 3 years of follow-up. Further, no significant difference in the incidence of adverse events was found between the two treatment groups.
Collectively, adjuvant radiochemotherapy after radical gastrectomy for stage III gastric cancer was associated with better survival outcomes than chemotherapy, without increase in adverse events.
尽管辅助治疗已被证明对胃癌有益，但辅助放化疗的应用仍存在争议。本文旨在探讨术后辅助放化疗对 III 期胃癌患者生存的影响。
回顾性分析 2014 年 1 月至 2019 年 12 月在我院接受治疗的 72 例 III 期胃癌患者的临床资料，根据治疗方案的不同分为化疗组（CT 组）和放化疗组（RCT 组）。对所有患者进行为期 3 年的随访，记录无病生存率（DFS）、总生存率（OS）和不良事件的发生情况。
在 CT 组和 RCT 组中，DFS 在第 1 年分别为 86.4%和 92.6%，第 2 年分别为 55.1%和 73.7%，第 3 年分别为 41.3%和 69.1%。在 3 年的随访期间，两组患者的 DFS 无显著差异。此外，在 CT 组和 RCT 组中，1 年、2 年和 3 年的 OS 分别为 95.6%和 96.3%、75.1%和 87.9%、50.3%和 74.2%，表明 RCT 组患者的 OS 在 3 年的随访中明显高于 CT 组。进一步分析发现，两组患者不良事件的发生率无显著差异。
与单纯化疗相比，根治性胃切除术后辅助放化疗可提高 III 期胃癌患者的生存获益，且不增加不良反应。
